Abstract
Atherosclerosis is a systemic inflammatory disease leading to lipid-laden inflammatory lesions in the arterial walls that may destabilize and rupture. It is becoming clear that addressing the “classical” risk factors for atherosclerosis does not entirely reduce the risk of cardiovascular events. Novel biomarkers to be used in highthroughput assays are necessary for diagnosis, for determination of the residual risk and for monitoring the effects of the therapy. Since inflammation is a hallmark of atherosclerosis, tests for pro-inflammatory biomarkers have been introduced such as for hsCRP, fibrinogen and IL-6, with many more at different stages of development.
There has been a dearth of novel approaches for the diagnosis and management of atherosclerosis, reflected in a continuous reliance on LDL cholesterol as a proven target of investigations. To bring another perspective, here we briefly overview the accumulated epidemiological and sero-epidemiological evidence suggesting systemic infections as a component of atherosclerotic inflammations. We have shown that different individuals’ plaques are colonized with different bacterial species (atherosclerosis microbiota). Most of the time the pathogens are likely in an intracellular state, shielded from the host immune responses. There are controlled clinical trials and metaanalyses that corroborate the infections, specifically periodontal disease as a contributing risk factor of atherosclerosis. Infection-related markers, including transcriptome signatures, may identify latent infection patients with sub-clinical disease. Thus, the emerging infection- associated markers of inflammation could complement the existing ones and their use as companion diagnostics for atherosclerosis should stimulate the growing field of personalized medicine within cardiovascular diseases.
Keywords: Atherosclerosis, biomarkers, inflammation, infection.
Current Pharmaceutical Design
Title:Infection-Associated Biomarkers of Inflammation in Atherosclerosis
Volume: 21 Issue: 13
Author(s): Emil Kozarov, Kurt Huber and Johann Wojta
Affiliation:
Keywords: Atherosclerosis, biomarkers, inflammation, infection.
Abstract: Atherosclerosis is a systemic inflammatory disease leading to lipid-laden inflammatory lesions in the arterial walls that may destabilize and rupture. It is becoming clear that addressing the “classical” risk factors for atherosclerosis does not entirely reduce the risk of cardiovascular events. Novel biomarkers to be used in highthroughput assays are necessary for diagnosis, for determination of the residual risk and for monitoring the effects of the therapy. Since inflammation is a hallmark of atherosclerosis, tests for pro-inflammatory biomarkers have been introduced such as for hsCRP, fibrinogen and IL-6, with many more at different stages of development.
There has been a dearth of novel approaches for the diagnosis and management of atherosclerosis, reflected in a continuous reliance on LDL cholesterol as a proven target of investigations. To bring another perspective, here we briefly overview the accumulated epidemiological and sero-epidemiological evidence suggesting systemic infections as a component of atherosclerotic inflammations. We have shown that different individuals’ plaques are colonized with different bacterial species (atherosclerosis microbiota). Most of the time the pathogens are likely in an intracellular state, shielded from the host immune responses. There are controlled clinical trials and metaanalyses that corroborate the infections, specifically periodontal disease as a contributing risk factor of atherosclerosis. Infection-related markers, including transcriptome signatures, may identify latent infection patients with sub-clinical disease. Thus, the emerging infection- associated markers of inflammation could complement the existing ones and their use as companion diagnostics for atherosclerosis should stimulate the growing field of personalized medicine within cardiovascular diseases.
Export Options
About this article
Cite this article as:
Kozarov Emil, Huber Kurt and Wojta Johann, Infection-Associated Biomarkers of Inflammation in Atherosclerosis, Current Pharmaceutical Design 2015; 21 (13) . https://dx.doi.org/10.2174/1381612821666141129173343
DOI https://dx.doi.org/10.2174/1381612821666141129173343 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Implications of Angiotensin II in Central Nervous System on Exercise Performance
Current Protein & Peptide Science Sympathetic Activation in Hypertension and in Hypertension-Related Metabolic Disease
Current Hypertension Reviews Editorial [Hot Topic: Natural Products for the Healthy Heart (Guest Editor : Dipak K. Das)]
Current Pharmaceutical Biotechnology Biomarkers Associated with Vulnerable Atheromatous Plaque
Current Medicinal Chemistry Contextualizing Genetics for Regional Heart Failure Care
Current Cardiology Reviews Clinical Impacts in Cardiovascular Molecular Imaging: the Example of Cardiac Sympathetic Imaging in Heart Failure
Current Medical Imaging Genetic Variability of Matrix Metalloproteinase Genes in Cardiovascular Disease
Current Topics in Medicinal Chemistry Recent Advance in Isoform-Specific Regulation of Adenylyl Cyclase
Current Enzyme Inhibition Subfractions and Subpopulations of HDL: An Update
Current Medicinal Chemistry Proteomic and Bioinformatic Analysis of Trypanosoma cruzi Chemotherapy and Potential Drug Targets: New Pieces for an Old Puzzle
Current Drug Targets Nanoparticulate Iron Oxide Contrast Agents for Untargeted and Targeted Cardiovascular Magnetic Resonance Imaging
Current Nanoscience Imaging and Laboratory Biomarkers in Cardiovascular Disease
Current Pharmaceutical Design Wound-Associated Skin Fibrosis: Mechanisms and Treatments Based on Modulating the Inflammatory Response
Endocrine, Metabolic & Immune Disorders - Drug Targets Current Research on Opioid Receptor Function
Current Drug Targets Evaluating Oxidative Stress in Human Cardiovascular Disease: Methodological Aspects and Considerations
Current Medicinal Chemistry Novel Molecules Targeting Dyslipidemia and Atherosclerosis
Current Medicinal Chemistry A Review of the Characteristics, Properties and Methods for Quantification of Roxithromycin
Current Pharmaceutical Analysis Anti-Hyperglycemic and Hypolipidemic Effects of Different Aloe vera (Aloe Barbadensis Miller) Extracts in the Management of Obesity and Diabetes
Current Nutrition & Food Science Angiogenesis Inhibitors: Current & Future Directions
Current Pharmaceutical Design Dietary Antioxidants and Oxidative Stress from a Human and Plant Perspective: A Review
Current Nutrition & Food Science